Wall Street analysts expect Merck (MRK Quick QuoteMRK - Free Report) to post quarterly loss of -$0.26 per share in its upcoming report, which indicates a year-over-year decline of 112.2%. Revenues are expected to be $16.33 billion, up 3.3% from the year-ago quarter.

The consensus EPS estimate for the quarter has undergone an upward revision of 1.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Bearing this in mind, let's now explore the average estimates of specific Merck metrics that are commonly monitored and projected by Wall Street analysts.

The combined assessment of analysts suggests that 'Sales- Oncology- Alliance Revenue- Lynparza' will likely reach $356.54 million. The estimate points to a change of -3.6% from the year-ago quarter.

The consensus among analysts is that 'Sales- Oncology- Keytruda' will reach $8.06 billion. The estimate points to a change of +1.3% from the year-ago quarter.

Analysts predict that the 'Sales- Hospital Acute Care- Zerbaxa' will reach $79.95 million. The estimate indicates a year-over-year change of +8%.

The average prediction of analysts places 'Sales- Hospital Acute Care- Prevymis' at $254.29 million. The estimate indicates a year-over-year change of +11.5%.

According to the collective judgment of analysts, 'Sales- Hospital Acute Care- Bridion - U.S.' should come in at $328.80 million. The estimate indicates a change of -20% from the prior-year quarter.

Analysts forecast 'Sales- Oncology- Keytruda - International' to reach $3.33 billion. The estimate indicates a change of +3.8% from the prior-year quarter.

The consensus estimate for 'Sales- Diabetes- Janumet - U.S.' stands at $47.60 million. The estimate indicates a year-over-year change of -30%.

Analysts expect 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' to come in at $166.31 million. The estimate suggests a change of -4.4% year over year.

Analysts' assessment points toward 'Sales- Oncology- Alliance revenue- Lynparza - International' reaching $190.23 million. The estimate suggests a change of -2.5% year over year.

The collective assessment of analysts points to an estimated 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' of $157.00 million. The estimate indicates a year-over-year change of -14.2%.

It is projected by analysts that the 'Sales- Oncology- Alliance revenue- Lenvima - International' will reach $82.27 million. The estimate points to a change of -0.9% from the year-ago quarter.

Based on the collective assessment of analysts, 'Sales- Hospital Acute Care- Zerbaxa - U.S.' should arrive at $47.95 million. The estimate indicates a change of +6.6% from the prior-year quarter.

Over the past month, Merck shares have recorded returns of +4% versus the Zacks S&P 500 composite's -1.5% change. Based on its Zacks Rank #4 (Sell), MRK will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .